Article

Mini glaucoma shunt reimbursement increases under new classification

Optonol announced in a prepared statement that its proprietary mini glaucoma shunt (Ex-PRESS) will be paid under a new ambulatory payment classification (APC) beginning Jan. 1, 2009.

Neve Ilan, Israel-Optonol announced in a prepared statement that its proprietary mini glaucoma shunt (Ex-PRESS) will be paid under a new ambulatory payment classification (APC) beginning Jan. 1, 2009.

The shunt now is assigned to APC 673 (Level IV Anterior Segment Eye Procedures), according to the published Centers for Medicare and Medicaid Services (CMS) 2009 Hospital Outpatient Prospective System Final Rule. In the hospital outpatient setting, the national average reimbursement for the shunt increased from $1476.16 to $2705.35. In the Ambulatory Surgery Center (ASC) setting, the payment increased from $949 to $1652.98.

“We are pleased that CMS reconsidered the reimbursement level to make the procedure available to Medicare beneficiaries,” said Patrick King, president of Optonol. “This will allow glaucoma surgeons access to the . . . mini glaucoma shunt in both the hospital outpatient setting and the ASC.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.